Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.59 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.59 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.59 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30605654 | 1.00 | ALDH1A1 (0.59) | ALDH1A1HTTHPGDMAPK1MAPK10 | |
| SCHEMBL230452 | 0.85 | FGFR1 (0.59) | ALDH1A1HTTHPGDMAPK1MAPK10 | |
| SCHEMBL14805907 | 0.81 | DYRK1A (0.45) | ALDH1A1HTTHPGDMAPK1MAPK10 | |
| SCHEMBL19848089 | 0.80 | ALDH1A1 (0.58) | ALDH1A1HTTHPGDMAPK1MAPK10 | |
| SCHEMBL19756736 | 0.80 | DYRK1A (0.44) | ALDH1A1HTTHPGDMAPK1MAPK10 | |
| SCHEMBL19848392 | 0.79 | ALDH1A1 (0.56) | ALDH1A1HTTHPGDMAPK1MAPK10 | |
| SCHEMBL19911346 | 0.78 | MTNR1A (0.64) | ALDH1A1HTTHPGDMAPK1MAPK10 | |
| SCHEMBL9707233 | 0.78 | KMT2A (0.57) | ALDH1A1HTTHPGDMAPK1MAPK10 | |
| SCHEMBL2981473 | 0.78 | CYP1A1 (0.50) | ALDH1A1HPGDMAPK1KMT2AKDM4E | |
| SCHEMBL2981476 | 0.78 | CYP1A1 (0.50) | ALDH1A1HPGDMAPK1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630536-B2 | Cyanotriazine derivative, preparation method therefor, and application thereof | CHENGDU FANXI BIOPHARMA CO., LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| CN-117126143-A | Method for synthesizing (tetrahydrofuran-2-yl) heteroaromatic compound | 苏州大学 | 2023-11-28 | — | — | CN | disclosed |
| US-20230312527-A1 | CYANOTRIAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | CHENGDU FANXI BIOPHARMA CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230312527-A1 | CYANOTRIAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | CHENGDU FANXI BIOPHARMA CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| EP-4201927-A1 | CYANOTRIAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Chengdu Fanxi Biopharma Co., Ltd. (CN) | 2023-06-28 | — | — | EP | disclosed |
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| US-20170037059-A1 | GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9481675-B2 | Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20130079323-A1 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | ALDH1A1 504/4885HTT 1337/4885HPGD 486/4885 |
| US-12630536-B2 | Cyanotriazine derivative, preparation method therefor, and application thereof | THRB, SLC10A1, THRA | ALDH1A1 1905/4885HTT 304/4885HPGD 3613/4885 |
| US-20170037059-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | ALDH1A1 2837/4885HTT 4778/4885HPGD 1233/4885 |
| US-20230312527-A1 | CYANOTRIAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | THRB, SLC5A1, SLC10A1 | ALDH1A1 2753/4885HTT 729/4885HPGD 2014/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | ALDH1A1 504/4885HTT 1337/4885HPGD 486/4885 |
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | ALDH1A1 3497/4885HTT 1107/4885HPGD 2179/4885 |
| US-20130079323-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | ALDH1A1 2837/4885HTT 4778/4885HPGD 1233/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | ALDH1A1 3497/4885HTT 1107/4885HPGD 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.